Agios Pharmaceuticals Inc

24.08.2026 г., 19:36 ч. UTC

Agios Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close amid broader market volatility linked to geopolitical events.

21.08.2026 г., 19:36 ч. UTC

Agios Pharmaceuticals Inc shares are lower during Friday's session amid rising U.S. Treasury yields and ongoing geopolitical tensions. No specific news was identified.

20.08.2026 г., 20:01 ч. UTC

Agios Pharmaceuticals Inc. shares are lower today, driven by a significant downturn in the Biotechnology sector and heightened trading volume.

19.08.2026 г., 20:06 ч. UTC

Agios Pharmaceuticals shares are higher today, though they pulled back from a session high. Broader market sentiment may be influenced by rising cryptocurrency values.

18.08.2026 г., 22:51 ч. UTC

Agios Pharmaceuticals shares are lower in after-market hours, amid broader negative sentiment linked to rising sovereign bond yields and persistent inflation risks.

17.08.2026 г., 19:41 ч. UTC

Agios Pharmaceuticals shares are rising as Cantor Fitzgerald maintains an Overweight rating ahead of the November 1 PDUFA date for mitapivat.

14.08.2026 г., 19:46 ч. UTC

Agios Pharmaceuticals Inc shares are higher today, though no specific news explains the movement. Earlier, shares peaked before dipping later in the session.

12.08.2026 г., 20:01 ч. UTC

Agios Pharmaceuticals Inc shares are higher today amid unusually high trading volume. The stock has gained significantly since Tuesday's close.

11.08.2026 г., 19:26 ч. UTC

Agios Pharmaceuticals Inc shares are higher today, with no specific news driving the move. Market focus remains on upcoming U.S. inflation reports.

10.08.2026 г., 21:01 ч. UTC

Agios Pharmaceuticals Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains below its 20-day moving average.

6.08.2026 г., 19:32 ч. UTC

Agios Pharmaceuticals shares are higher today, continuing an upward trend since Wednesday. The stock peaked earlier in the session before a slight pullback.

5.08.2026 г., 19:56 ч. UTC

Agios Pharmaceuticals is under investigation regarding its decision on tebapivat, contributing to lower trading activity today amid ongoing investor concerns.

4.08.2026 г., 20:02 ч. UTC

Agios Pharmaceuticals Inc shares are higher today amid broader market gains, supported by falling crude oil prices and comments on potential peace talks with Iran.

3.08.2026 г., 20:06 ч. UTC

Agios Pharmaceuticals Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

31.07.2026 г., 22:51 ч. UTC

Agios Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market declines amid mixed tech earnings and rising U.S. Treasury yields.

30.07.2026 г., 20:08 ч. UTC

Agios Pharmaceuticals shares are lower today amid mixed economic signals and unusually high trading volume. The stock has declined since Wednesday's close.

29.07.2026 г., 20:51 ч. UTC

Agios Pharmaceuticals Inc shares gained in after-market trading, rebounding from a session low despite broader market pressures from rising crude oil prices and geopolitical tensions.

28.07.2026 г., 20:02 ч. UTC

Agios Pharmaceuticals shares are lower amid an investigation into potential claims following the halted development of tebapivat for sickle cell disease.

27.07.2026 г., 20:01 ч. UTC

Agios Pharmaceuticals Inc shares are higher during Monday's session, reaching a notable peak earlier in the day. No specific news was identified for the move.

24.07.2026 г., 23:21 ч. UTC

Agios Pharmaceuticals shares are higher in after-market trading, supported by a decline in initial jobless claims, indicating a robust labor market.

22.07.2026 г., 22:41 ч. UTC

Agios Pharmaceuticals shares are lower in after-market trading, continuing a three-session decline amid broader market concerns over rising crude oil prices and inflation.

21.07.2026 г., 19:01 ч. UTC

Agios Pharmaceuticals shares declined after discontinuing tebapivat development for sickle cell disease, despite some trial improvements. The stock remains lower since Monday's close.